文献速递肾小球疾病

基于适配体的蛋白质组学血清蛋白特征用于微小病变肾病与膜性肾病

Serum Protein Signatures Using Aptamer-Based Proteomics for Minimal Change Disease and Membranous Nephropathy.
PubMed 文献 · Kidney Int Rep · 2022-04-14

研究采用SOMAscan定量蛋白质组学检测成人微小病变肾病(MCD,n=15)、膜性肾病(MN,n=37)与健康对照(n=20)的血清,分别鉴定出208和244种蛋白可将MCD、MN与健康对照高度显著区分(BH P<0.0001),157种蛋白可区分MN与MCD(BH P<0.05),系统生物学分析提示细胞死亡和炎症是MN与MCD及健康对照的关键差异通路。

要点

  • SOMAscan检测到208种蛋白区分MCD与健康对照,244种区分MN与健康对照(BH P<0.0001)。
  • 157种蛋白可区分MN与MCD(BH P<0.05),44种蛋白为MN特异性。
  • 细胞死亡和炎症通路是MN与MCD及健康对照的关键差异通路。

核心结论

  • SOMAscan是肾小球疾病生物标志物开发中有前景的蛋白质组学平台。
  • 需在更大患者队列中验证更多发现阶段的生物标志物,之后这些数据才能转化用于临床诊疗。

研究设计与样本

  • 研究应用定量SOMAscan蛋白质组学检测成人MCD患者(n=15)、MN患者(n=37)和健康对照(n=20)的血清。
  • 对SOMAscan检测到的1305种蛋白,采用多种统计学检验、表达模式分析和系统生物学分析评估其关联。

主要发现

  • 分别有208种和244种蛋白可将MCD和MN与健康对照高度显著区分(BH P<0.0001)。
  • 157种蛋白可区分MN与MCD(BH P<0.05)。
  • 在MCD中,65种蛋白与MN及健康对照相比存在差异表达。
  • 与MCD和健康对照相比,44种有区分力的蛋白特异性与MN相关。
  • 系统生物学分析显示细胞死亡和炎症是MN与MCD及健康对照的关键差异通路;与健康受试者相比,MN和MCD均证实脂肪酸代谢通路失调。

局限性

  • 需在更大患者队列中验证更多发现阶段的生物标志物,之后这些数据才能转化用于临床诊疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Minimal change disease (MCD) and membranous nephropathy (MN) are glomerular diseases (glomerulonephritis [GN]) that present with the nephrotic syndrome. Although circulating PLA2R antibodies have been validated as a biomarker for MN, the diagnosis of MCD and PLA2R-negative MN still relies on the results of kidney biopsy or empirical corticosteroids in children. We aimed to identify serum protein biomarker signatures associated with MCD and MN pathogenesis using aptamer-based proteomics. METHODS: Quantitative SOMAscan proteomics was applied to the serum of adult patients with MCD (n = 15) and MN (n = 37) and healthy controls (n = 20). Associations between the 1305 proteins detected with SOMAscan were assessed using multiple statistical tests, expression pattern analysis, and systems biology analysis. RESULTS: A total of 208 and 244 proteins were identified that differentiated MCD and MN, respectively, with high statistical significance from the healthy controls (Benjamin-Hochberg [BH] P < 0.0001). There were 157 proteins that discriminated MN from MCD (BH P < 0.05). In MCD, 65 proteins were differentially expressed as compared with MN and healthy controls. When compared with MCD and healthy controls, 44 discriminatory proteins were specifically linked to MN. Systems biology analysis of these signatures identified cell death and inflammation as key pathways differentiating MN from MCD and healthy controls. Dysregulation of fatty acid metabolism pathways was confirmed in both MN and MCD as compared with the healthy subjects. CONCLUSION: SOMAscan represents a promising proteomic platform for biomarker development in GN. Validation of a greater number of discovery biomarkers in larger patient cohorts is needed before these data can be translated for clinical care.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Muruve DA, Debiec H, Dillon ST, et al. Serum Protein Signatures Using Aptamer-Based Proteomics for Minimal Change Disease and Membranous Nephropathy. Kidney Int Rep. 2022. PMID: 35812291. doi:10.1016/j.ekir.2022.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。